Literature DB >> 19757556

Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.

J A Conlon1, T N Mather, P Tanner, G Gallo, R H Jacobson.   

Abstract

In a blinded, controlled study, thirty purpose-bred, Borrelia burgdorferi negative, mixed-breed dogs 10 to 12 weeks of age were randomly divided into three groups of ten animals each for the purpose of evaluating a recombinant nonadjuvanted B. burgdorferi OspA vaccine (Recombitek Lyme [Merial Limited]) for efficacy and safety. Two groups received two doses of two different lots ofa nonadjuvanted, OspA, recombinant vaccine; the third group served as nonvaccinated controls. All dogs were challenged 3 weeks after the second vaccination with blacklegged deer ticks (Ixodes scapularis) harvested from a B. burgdorferi endemic area in Rhode Island. Clinical signs, antibody titers by ELISA, Western blot assays, and isolation and polymerase chain reaction analyses of spirochetes from biopsy specimens were used to evaluate vaccine efficacy. Direct fluorescent antibody assay was used to evaluate the infection rate in the challenge ticks and in naïve ticks allowed to feed on study dogs after the dogs were infected (xenodiagnosis). Vaccinates responded with high levels of antibodies (determined by ELISA and measured by optical density [OD]), which did not rise after challenge. Vaccinates demonstrated no clinical signs, negative isolation of spirochetes on biopsy, only an OspA antibody pattern on Western blot assay, and negative isolation of spirochetes on biopsy, confirming that the vaccine blocked infection with B. burgdorferi in all vaccinated dogs (20/20). Control dogs demonstrated clinical signs (2/10), antibodies characteristic of infection with B. burgdoferi (10/10), isolation of spirochetes (10/10), and polymerase chain reaction (PCR) detection of spirochetes (9/10). The recombinant, nonadjuvanted B. burgdoferi vaccine protected 100% of vaccinates against infection after a severe challenge that infected 100% of control dogs. The OspA vaccine proved to be highly safe and effective in this study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 19757556

Source DB:  PubMed          Journal:  Vet Ther        ISSN: 1528-3593


  12 in total

1.  Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens.

Authors:  Vanessa Cook; Alan G Barbour
Journal:  Ticks Tick Borne Dis       Date:  2015-04-28       Impact factor: 3.744

2.  Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.

Authors:  Jasmin Federizon; Amber Frye; Wei-Chiao Huang; Thomas M Hart; Xuedan He; Christopher Beltran; Ashley L Marcinkiewicz; Iain L Mainprize; Melanie K B Wills; Yi-Pin Lin; Jonathan F Lovell
Journal:  Vaccine       Date:  2019-11-11       Impact factor: 3.641

3.  Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs.

Authors:  Bettina Wagner; Heather Freer; Alicia Rollins; David Garcia-Tapia; Hollis N Erb; Christopher Earnhart; Richard Marconi; Patrick Meeus
Journal:  Clin Vaccine Immunol       Date:  2012-02-15

4.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

5.  Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.

Authors:  Andrew K Eschner; Kristen Mugnai
Journal:  Parasit Vectors       Date:  2015-02-10       Impact factor: 3.876

6.  Immunization with a Borrelia burgdorferi BB0172-derived peptide protects mice against lyme disease.

Authors:  Christina M Small; Dharani K Ajithdoss; Aline Rodrigues Hoffmann; Waithaka Mwangi; Maria D Esteve-Gassent
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

7.  A Bayesian spatio-temporal model for forecasting the prevalence of antibodies to Borrelia burgdorferi, causative agent of Lyme disease, in domestic dogs within the contiguous United States.

Authors:  Stella C Watson; Yan Liu; Robert B Lund; Jenna R Gettings; Shila K Nordone; Christopher S McMahan; Michael J Yabsley
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

8.  ACVIM consensus update on Lyme borreliosis in dogs and cats.

Authors:  Meryl P Littman; Bernhard Gerber; Richard E Goldstein; Mary Anna Labato; Michael R Lappin; George E Moore
Journal:  J Vet Intern Med       Date:  2018-03-22       Impact factor: 3.333

9.  Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.

Authors:  Deborah A Grosenbaugh; Karelle De Luca; Pierre-Yves Durand; Bradley Feilmeier; Kristopher DeWitt; Cecile Sigoillot-Claude; Marie-Line Sajous; Michael J Day; Frederic David
Journal:  BMC Vet Res       Date:  2018-10-16       Impact factor: 2.741

Review 10.  Vaccination against Lyme disease: past, present, and future.

Authors:  Monica E Embers; Sukanya Narasimhan
Journal:  Front Cell Infect Microbiol       Date:  2013-02-12       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.